CD19 and acute lymphoblastic leukemia: According to the available published and historical data of CD19 BiTE® Blinatumomab for ALL treatment, BiTE would bring better clinical benefit in patients who received less prior lines of treatment, since the T effector cell function would be better reserved (or less exhausted) than patients with heavier prior treatments [115,116].